Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2021-10-14 , DOI: 10.1002/alz.12480
Duygu Tosun _{1,

2} , Zeynep Demir ₂ , Dallas P Veitch _{1,

2} , Daniel Weintraub ₃ , Paul Aisen ₄ , Clifford R Jack ₅ , William J Jagust ₆ , Ronald C Petersen _{7,

8} , Andrew J Saykin _{9,

10,

11} , Leslie M Shaw ₁₂ , John Q Trojanowski ₁₂ , Michael W Weiner _{1,

2} ,

Affiliation

San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, San Diego, California, USA.
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
School of Public Health and Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.
Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Amyloid beta (Aβ), tau, and neurodegeneration jointly with the Alzheimer's disease (AD) risk factors affect the severity of clinical symptoms and disease progression.

中文翻译：